Top

Global Huntington's Disease Therapeutics Market 2014-2018

Category : Healthcare  | Published Date : Oct-2014 | Pages : 72
enquire GET DISCOUNT
About Huntington's Disease 
Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. People with Huntington's disease often develop chorea that causes involuntary muscle movements of hands, face, trunk, and feet. The behavioural disorders associated with the disease include depression, psychosis, and changes in personality. Other symptoms of the disease include speech impairment, anxiety, stress, and difficulty in swallowing. People suffering from Huntington's disease usually develop symptoms in their mid-30s and 40s. However, in few cases, disease symptoms appear in childhood or teens. The former case represents the adult-onset form of the disease, while the latter is the early-onset form. The early-onset form is associated with symptoms such as tremors, slow movements, and rigidity. Children with early-onset disease rarely live to adulthood. Currently, there is no approved treatment for Huntington's disease.
TechNavio's analysts forecast the Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Huntington's Disease Therapeutics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of drugs approved for the treatment of symptoms of Huntington's disease. 
TechNavio's report, the Global Huntington's Disease Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Huntington's Disease Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA        
Key Vendors
• Lundbeck 
• Valeant Pharmaceuticals International 
Other Prominent Vendors
• Auspex Pharmaceuticals
• GlaxoSmithKline
• Ipsen
• Omeros 
• Palobiofarma
• Pfizer
• Prana Biotechnology
• Raptor Pharmaceutical
• Siena Biotech
• SOM Biotech
• Teva Pharmaceutical Industries
Market Driver
• Unmet Medical Needs
• For a full, detailed list, view our report
Market Challenge
• Poor Diagnosis Rates
• For a full, detailed list, view our report
Market Trend
• Novel Mechanisms Targeted by Pipeline Candidates
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Prevalence of Huntington's Disease
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Drug Class
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.2 Market Share Analysis 2013
17.3 Potential Future Vendors
18. Clinical-stage Pipeline Candidates
19. Key Information of Clinical-stage Pipeline Candidates
19.1 SD-809ER
19.2 RP103
19.3 ABR-215062
19.4 BN82451
19.5 OMS824
19.6 PF-02545920
19.7 SEN0014196
19.8 TV-7820
19.9 PBT2
19.10 GSK356278
19.11 PBF-999
20. Discontinued Clinical-stage Pipeline Drugs
21. Key Vendor Analysis
21.1 H. Lundbeck
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Product Segmentation by Revenue 2013
21.1.4 Product Segmentation by Revenue 2012 and 2013
21.1.5 Geographical Segmentation by Revenue 2013
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 Valeant Pharmaceuticals International
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation by Revenue 2013
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Developments
21.2.8 SWOT Analysis
22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Prevalence of Huntington's Disease by Geography 2013
Exhibit 3: Global Huntington's Disease Therapeutics Market 2013-2018 (US$ million)
Exhibit 4: Global Huntington's Disease Therapeutics Market by Drug Class
Exhibit 5: Global Huntington's Disease Therapeutics Market by Geographical Segmentation 2013
Exhibit 6: Global Huntington's Disease Therapeutics Market Share Analysis 2013
Exhibit 7: Key Regulatory Approvals of Tetrabenazine
Exhibit 8: Key Events of Xenazine
Exhibit 9: Valeant Pharmaceuticals International Inc.: Sales of Xenazine 2008-2013 (US$ million)
Exhibit 10: Valeant Pharmaceuticals International Inc.: Sales of Xenazine by Geography 2013
Exhibit 11: H. Lundbeck A/S: Sales of Xenazine 2009-2013 (US$ million)
Exhibit 12: H. Lundbeck A/S: Quaterly Sales of Xenazine 2009-2013 (US$ million)
Exhibit 13: H. Lundbeck: Business Segmentation by Revenue 2013
Exhibit 14: H. Lundbeck: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 15: H. Lundbeck: Geographical Segmentation by Revenue 2013
Exhibit 16: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2013
Exhibit 17: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 18: Valeant Pharmaceuticals International Inc.: Sales by Geography 2013


...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 2500
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top